Dihydro-benzo [B] [1,4] diazepin-2-one derivatives
AssigneeHoffmann-La Roche Inc.
InventorsGeo Adam, Erwin Goetschi, Vincent Mutel, Juergen Wichmann, Thomas Johannes Woltering
Life of this patent
Estimating the term…
Abstract
This invention is a dihydro-benzo[b][1,4]diazepin-2-one derivative of the formula wherein R1, R2, R3 and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation and a method of treatment or prevention of acute and/or chronic neurological disorders by administering an effective amount of the compound of formula I or a pharmaceuticall acceptable salt thereof.
Claims24
A compound of formula
- wherein
- R1 is selected from the group consisting of cyano,
- fluoro-lower alkyl,
- lower alkoxy,
- fluoro-lower alkoxy,
- unsubstituted pyrrol-1-yl, and pyrrol-1-yl substitued by between one to three substituents selected from the group consisting of
- fluoro, chloro, cyano, unsubstituted phenyl, or phenyl substituted by a substituent selected from the group consisting of halogen,
- —(CH2)1-4-hydroxy, fluoro-lower alkyl, lower alkyl, —(CH2)n-lower alkoxy,
- —(CH2)n—C(O)O—R″, —(CH2)1-4—NR′R″, hydroxy-lower alkoxy and
- —(CH2)n—CONR′R″;
- R2 is selected from the group consisting of
- halogen,
- hydroxy,
- lower alkyl,
- fluoro-lower alkyl,
- lower alkoxy,
- hydroxymethyl,
- hydroxyethoxy,
- lower alkoxy-(ethoxy)m, wherein m=1 to 4,
- lower alkoxymethyl,
- cyanomethoxy,
- morpholine-4-yl,
- thiomorpholine-4-yl,
- 1-oxothiomorpholine-4-yl,
- 1,1-dioxothiomorpholine-4-yl,
- 4-oxo-piperidine-1-yl
- 4-alkoxy-piperidine-1-yl,
- 4-hydroxy-piperidine-1-yl,
- 4-hydroxyethoxy-piperidine-1-yl,
- 4-lower alkyl-piperazine-1-yl,
- alkoxycarbonyl,
- 2-dialkylamino-ethylsulfanyl,
- N,N-bis lower alkylamino lower alkyl,
- carbamoylmethyl,
- alkylsulfonyl
- lower alkoxycarbonyl-lower alkyl,
- alkylcarboxy-lower alkyl,
- carboxy-lower alkyl,
- alkoxycarbonylmethylsulfanyl,
- carboxymethylsulfanyl,
- 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl,
- carboxy-lower alkoxy,
- cyano-lower alkyl,
- 2,3-dihydroxy-lower alkoxy,
- carbamoylmethoxy,
- 2-oxo-[1,3]-dioxolan-4-yl-lower alkoxy,
- N-(2-hydroxy-lower alkyl)-N-lower alkyl amino,
- hydroxycarbamoyl-lower alkoxy,
- 2,2-dimethyl-tetrahydro-[1,3]dioxolo[4,5c]-pyrrol-5-yl,
- lower alkoxy-carbamoyl-lower alkoxy,
- 3R-hydroxy-pyrrolidin-1-yl,
- 3,4-dihydroxy-pyrrolidin-1-yl,
- 2-oxo-oxazolidin-3-yl,
- lower alkyl-carbamoylmethoxy,
- aminocarbamoyl-lower alkoxy, and, when R1 is unsubstituted pyrrol-1-yl or
- pyrrol-1-yl substituted as defined above, hydrogen;
- Y is —CH═ or ═N—;
- R3 is halogen,
- lower alkyl,
- fluoro-lower alkyl,
- lower alkoxy,
- cyano,
- —(CH2)n—C(O)—OR″,
- —(CH2)n—C(O)—NR′R″,
- or is an unsubstituted five-membered aromatic heterocycle or a five-membered aromatic heterocycle, substituted by halogen, fluoro-lower alkyl, fluoro-lower alkoxy, cyano, —(CH2)n—NR′R″, —(CH2)n—C(O)—OR″, —(CH2)n—C(O)—NR′R″, —(CH2)n—SO2—NR′R″, —(CH2)n—C(NH2)═NR″, hydroxy, lower alkoxy, lower alkylthio, lower alkyl, or lower alkyl substituted by fluoro, hydroxy, lower alkoxy, cyano or carbamoyloxy;
- R′ is selected from the group consisting of hydrogen,
- lower alkyl,
- C3-C6-cycloalkyl,
- fluoro-lower alkyl and
- 2-lower alkoxy lower alkyl;
- R″ is selected from the group consisting of hydrogen,
- lower alkyl,
- C3-C6-cycloalkyl,
- fluoro-lower alkyl,
- 2-lower alkoxy lower alkyl,
- —(CH2)2-4-di-lower alkylamino,
- —(CH2)2-4-morpholinyl,
- —(CH2)2-4-pyrrolidinyl,
- —(CH2)2-4-piperidinyl and
- 3-hydroxy-lower alkyl;
- and
- n is 0, 1, 2, 3 or 4;
- or a pharmaceutically acceptable addition salt thereof.
The compound, 4-(4-Oxo-7-pyrrol-1-yl-4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl)-pyridine-2-carbonitrile.
Dependencies are inferred from the claim text.